[Transaldolase deficiency - clinical outcome, pathogenesis, diagnostic process].

Transaldolase deficiency remains an underdiagnosed condition within the spectrum of pentose phosphate pathway disorders. Prior research has shown that most cases are identified through newborn screening or clinical suspicion of metabolic disease. No prior work had resolved the exact clinical variability across diagnosed patients. This gap motivated a synthesis of all known cases to date. The disorder affects glucose metabolism and may lead to oxidative stress. It was already known that transaldolase deficiency is autosomal recessive. However, the full range of symptoms and diagnostic markers remained unclear. This paper contributes a diagnostic algorithm to guide clinicians.

The aim was to clarify the clinical features, pathogenesis, and diagnostic process of transaldolase deficiency. The researchers propose that a structured approach is needed for accurate diagnosis. They focus on presenting a comprehensive review of 33 reported cases. The motivation is to improve recognition of this rare disorder. The authors also aim to summarize the pathophysiological mechanisms involved. They seek to provide a clear diagnostic framework for clinicians. The study does not propose new treatments or interventions. Instead, it emphasizes diagnostic accuracy and clinical awareness.

The researchers reviewed all published cases of transaldolase deficiency. They compiled clinical data from 33 patients identified globally. The authors used a systematic approach to analyze symptoms, laboratory findings, and genetic data. They synthesized information on clinical presentation and diagnostic markers. The study does not involve new experiments or patient recruitment. Instead, it relies on literature review and case aggregation. The authors also developed a stepwise diagnostic algorithm. The approach is purely descriptive and analytical.

The strongest finding is the identification of 33 patients with transaldolase deficiency. The majority of cases were diagnosed through newborn screening or clinical suspicion. Symptoms include jaundice, anemia, and developmental delays. Laboratory findings often show elevated lactate and abnormal organic acids. Genetic testing confirmed mutations in the TALDO1 gene in all cases. The study reports that diagnostic delays are common due to nonspecific symptoms. The diagnostic algorithm includes biochemical screening and genetic confirmation. The authors emphasize the importance of early diagnosis for better outcomes.

The authors state that transaldolase deficiency presents with a range of clinical features. They propose that a structured diagnostic approach is essential for timely identification. The study suggests that newborn screening can aid in early diagnosis. The diagnostic algorithm presented may improve recognition rates. The authors note that clinical awareness is crucial for managing this disorder. They suggest that further case reports may refine diagnostic criteria. The study does not claim that this is the only cause of metabolic symptoms. Instead, it highlights the importance of a systematic approach to diagnosis.